Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
RecruitingThis is a global Phase 2 study divided in two parts. Part A is a double-blind, randomized dose-range finding study in adults with moderate to severe asthma to confirm the dosing regimen of WIN378 that can be tested in future pivotal trials for efficacy and safety. Part B is a pivotal double-blind, randomized study to demonstrate the efficacy and safety of WIN378 in adults with severe uncontrolled asthma. Two dose levels of WIN378 will be tested against placebo to evaluate AAER, lung function, asthma control, asthma-related quality of life and other important efficacy endpoints.
PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereLos Angeles, California, United States + 72 more
SponsorWindward Bio
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724 ·
Severe Asthma RecruitingThe objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. Additional information is available at www.SOLAIRIA.com.
PhasePhase 3
TypeInterventional
Age12 Years – 80 Years
WhereNorthridge, California, United States + 157 more
SponsorGenerate Biomedicines
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
NCT07359846 ·
Severe Asthma RecruitingThe objective of this study is to assess the potential for GB-0895 to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. Additional information is available at www.SOLAIRIA.com.
PhasePhase 3
TypeInterventional
Age12 Years – 80 Years
WhereBakersfield, California, United States + 165 more
SponsorGenerate Biomedicines
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
NCT07532265 ·
Severe Asthma RecruitingA Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA
PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereLancaster, California, United States + 13 more
SponsorKinaset Therapeutics Inc
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
RecruitingThe main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life. The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.
Phase—
TypeObservational
Age6 Years
WhereBessemer, Alabama, United States + 82 more
SponsorSanofi
▾Tap for detailsClick for full details — eligibility, all locations, contacts ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RecruitingThis study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA). Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.
PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereBirmingham, Alabama, United States + 19 more
SponsorEnveda Therapeutics
▾Tap for detailsClick for full details — eligibility, all locations, contacts Ventilation and Perfusion in Asthmatics
RecruitingAssess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH).
PhasePhase 4
TypeInterventional
Age18 Years – 75 Years
WhereMiami, Florida, United States
SponsorUniversity of Miami
▾Tap for detailsClick for full details — eligibility, all locations, contacts Rademikibart IV for Acute Asthma and COPD Exacerbation
RecruitingA Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
PhasePhase 2
TypeInterventional
Age18 Years – 85 Years
WhereMiami, Florida, United States + 2 more
SponsorConnect Biopharm LLC
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)
RecruitingThe study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.
PhasePhase 3
TypeInterventional
Age12 Years – 80 Years
WhereSan Diego, California, United States + 12 more
SponsorGlaxoSmithKline
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
RecruitingThis study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).
PhasePhase 3
TypeInterventional
Age18 Years
WhereAventura, Florida, United States + 19 more
SponsorGlaxoSmithKline
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
RecruitingThe purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.
PhasePhase 2
TypeInterventional
Age4 Years – 11 Years
WhereBakersfield, California, United States + 43 more
SponsorAstraZeneca
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
RecruitingThis Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereLancaster, California, United States + 80 more
SponsorKymera Therapeutics, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
RecruitingThis Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.
PhasePhase 2
TypeInterventional
Age18 Years
WhereMiami, Florida, United States + 6 more
SponsorKymera Therapeutics, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RecruitingThe purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
PhasePhase 3
TypeInterventional
Age12 Years – 17 Years
WhereAnchorage, Alaska, United States + 156 more
SponsorAstraZeneca
▾Tap for detailsClick for full details — eligibility, all locations, contacts Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
RecruitingThis is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereBakersfield, California, United States + 222 more
SponsorAstraZeneca
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
RecruitingThe aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
PhasePhase 3
TypeInterventional
Age12 Years
WhereLittle Rock, Arkansas, United States + 16 more
SponsorGlaxoSmithKline
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma
RecruitingThe purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.
PhasePhase 3
TypeInterventional
Age12 Years – 80 Years
WhereBakersfield, California, United States + 15 more
SponsorPfizer
▾Tap for detailsClick for full details — eligibility, all locations, contacts